Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Product Portfolio > Late Stage

Products in Late Stage DevelopmentSpectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Spectrum's late-stage drug candidates include belinostat, an HDAC inhibitor in late-stage clinical development for peripheral T-cell lymphoma, and other solid tumors (including Carcinoma of Unknown Primary origin, etc.), apaziquone, a synthetic bio-reductive agent being investigated in the treatment of non muscle-invasive bladder cancer, and Captisol-enabled® melphalan, a new IV formulation of melphalan that has the potential to offer multiple advantages for clinicians and patients in the multiple myeloma transplant setting. Both drugs are being developed under Special Protocol Assessment (SPA) by the FDA.

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company


spectrum pharmaceuticals products